Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Adicionar filtros








Intervalo de ano
1.
Rev. chil. nutr ; 37(3): 340-351, Sept. 2010. ilus, tab
Artigo em Espanhol | LILACS | ID: lil-577400

RESUMO

Constipation is a complex disorder, which affects an important part of the population and results in an increase of gastrointestinal symptoms and in lower stool frequency. The addition of soluble fibers (prebiotics) and probiotic in foodstuffs has been proposed as a useful tool to improve digestive wellbeing of affected individuals. The aim of this study was to evaluate the effect of the daily consumption of Minishot, a milk drink with prebiotics (inulin I polydextrose) and probiotics (Bifidobacterium lactis BB12), on the digestive comfort of healthy and constipated subjects. We conducted a randomized, controlled, double blind clinical trial in 33 healthy subjects and 64 constipated subjects (< 3 stools I week). Subjects underwent a one-week observation period followed by two periods of two weeks of consumption of Minishot or placebo, separated between them by a two-week washout period. The volunteers recorded daily in a table the presence and severity of distracters and digestive symptoms and the number and consistency of stools. Neither Minishot nor the placebo affected the digestive wellbeing or the stool frequency and consistency in the control subjects. In the constipated subjects, both consumption of Minishot and the placebo improved digestive comfort and stool frequency. However, compared with the placebo, Minishot significantly decreased the frequency of hard stools and the proportion of subjects emitting them, and increased the frequency of normal stools.


La constipación es un trastorno complejo que afecta una parte importante de la población. El consumo de prebióticos y probióticos ha sido propuesta como una herramienta para mejorar el bienestar digestivo de las personas afectadas. El objetivo del estudio fue evaluar el efecto del consumo diario de una bebida láctea con inulina/polidextrosa y Bifidobacterium lactis Bbl2, Minishot, sobre el bienestar digestivo de sujetos sanos o constipados. Se realizó un ensayo clínico randomizado, controlado y en doble ciego en 33 sujetos sanos y 64 sujetos constipados (< 3 deposiciones / semana). Después de una semana de observación, cada sujeto tuvo 2 periodos de 2 semanas de consumo de Minishot o del placebo, espaciados entre si por 2 semanas de reposo. Los voluntarios registraron diariamente la presencia e intensidad de síntomas digestivos y el número y consistencia de deposiciones. El consumo de Minishot no afecto en forma importante el bienestar digestivo de los sujetos sanos ni alteró la frecuencia y consistencia de sus deposiciones. En los sujetos constipados, tanto el consumo de Minishot como del placebo mejoraron el bienestar digestivo y la frecuencia de deposición. Comparado con el placebo, el consumo de Minishot disminuyó significativamente la frecuencia de deposiciones muy duras y la proporción de sujetos emitiéndolas, y aumento la frecuencia de deposiciones normales/blandas y la proporción de sujetos emitiéndolas.


Assuntos
Humanos , Feminino , Adulto , Bebidas , Bifidobacterium , Laticínios , Constipação Intestinal/terapia , Inulina/uso terapêutico , Probióticos/uso terapêutico , Defecação , Digestão , Método Duplo-Cego
2.
Arch. latinoam. nutr ; 59(4): 358-368, dic. 2009. ilus, tab
Artigo em Espanhol | LILACS | ID: lil-588639

RESUMO

Las enfermedades gastrointestinales siguen siendo un problema de salud pública mundial. El avance de la ciencia muestra que cambios en el balance adecuado de la microflora intestinal (MI) juegan un papel crucial en la patogénesis. La evidencia apunta a que una manera de modular esta MI es a través del uso de oligosacáridos prebióticos, que estimulan el crecimiento de bacterias benéficas y que a la vez aumentan la resistencia a la invasión por patógenos. Estudios con animales indican que el consumo de carbohidratos prebióticos podría estar implicado en la prevención y tratamiento de diarreas. En infantes humanos sanos, los estudios revelan que el consumo de mezclas de prebióticas (galactooligosacáridos/fructooligosacáridos, inulina/galactooligosacáridos) disminuyen la incidencia de fiebre, de infecciones y de patógenos gastrointestinales. Lo anterior representa un gran potencial para los alimentos funcionales que los contienen, principalmente las fórmulas infantiles. Sin embargo, los estudios de prevención de diarreas mediante el suministro de prebióticos en personas con una microflora intestinal alterada no son concluyentes, sobre todo aquellos practicados en ancianos, personas con problemas crónicos de inflamación intestinal y personas con diarreas asociadas a la toma de antibióticos. Lo anterior nos indica la necesidad de estudios bioquímicos y microbiológicos más profundos en humanos de diferentes edades y condiciones de salud intestinal, a fin de determinar en que condiciones, los prebióticos tienen algún efecto sobre las infecciones.


Gastrointestinal disorders are still a main world public health problem. Scientific progress shows that and inadequate balance in intestinal microbiota (IM) plays a crucial role in its pathogenesis. Evidence indicates that one way to modulate the IM is through the use of prebiotics. These oligosaccharides stimulate the growth of benefic bacteria and increase the resistance to invading pathogens. Research using animals show that the consumption of prebiotics could be implicated in prevention and treatment of diarrhea. Studies in healthy infants also indicate that the consumption of prebiotic mixtures (galactooligosaccharides/ fructooligosaccharides, inulin/ galactooligosaccharides) decreases the incidence of fever, infections and pathogens. These results represent a great potential for functional foods that contain prebiotics, mainly the infant formulas. However, results of other clinical studies for prebiotics effects on diarrhea are not conclusive. Specially those studies that include patients with an altered IM (like the elderly), patients with chronic intestinal inflammation and with diarrhea associated to antibiotic treatments. There is a need for more biochemical and microbiological studies in humans at different ages and intestinal health conditions, in order to determine when prebiotics may effectively function on infections.


Assuntos
Humanos , Masculino , Feminino , Gastroenteropatias/prevenção & controle , Enteropatias/prevenção & controle , Controle de Infecções , Inulina/uso terapêutico , Oligossacarídeos/uso terapêutico
3.
Indian J Physiol Pharmacol ; 1999 Apr; 43(2): 235-41
Artigo em Inglês | IMSEAR | ID: sea-106565

RESUMO

Alcoholic extract of root of Inula racemosa, was studied for its antiallergic effect in experimental models of type I hypersensitivity, viz. egg albumin induced passive cutaneous anaphylaxis (PCA) and mast cell degranulation in albino rats. The alcoholic extract was prepared by the process of continuous heat extraction. LD50 of this extract was found to be 2100 +/- 60 mg/kg, i.p. Assessment of protection against egg albumin induced passive cutaneous anaphylaxix by different doses of Inula racemosa was done by giving drug intraperitoneally or orally for seven days or once only. Mast cell degranulation studies were done by using compound 48/80 as degranulation agent with same dosage schedule. Inula racemosa (i.p. as well as p.o.) showed significant protection against egg albumin induced PCA. Protection against compound 48/80 induced mast cell degranulation by alcoholic extract of Inula racemosa (single dose) was similar to that of disodium cromoglycate. The seven days drug treatment schedule showed greater protection than disodium cromoglycate intraperitoneally. The results suggest that Inula racemosa possesses potent antiallergic properties in rats.


Assuntos
Animais , Feminino , Hipersensibilidade Imediata/induzido quimicamente , Inula , Inulina/uso terapêutico , Masculino , Mastócitos/patologia , Ayurveda , Anafilaxia Cutânea Passiva , Extratos Vegetais/uso terapêutico , Plantas Medicinais/química , Substâncias Protetoras/uso terapêutico , Ratos , p-Metoxi-N-metilfenetilamina/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA